COVID-19 Convalescent Plasma for Immuno-Compromised Patients
A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Epidemiology".
Deadline for manuscript submissions: closed (31 October 2022) | Viewed by 4145
Special Issue Editors
Interests: virology; hematology
Special Issues, Collections and Topics in MDPI journals
Interests: coagulation; convalescent plasma therapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
COVID-19 remains a life-threatening disease for severely immunocompromised patients, such as those with B-cell depletion, who do not develop protective immune responses even after multiple vaccine doses. These patients harbour chronic replication leading to significant intrahost variation and an inability to eradicate infection. Long-term treatment is required to prevent relapses. Among the currently authorized treatments, small-chemical antivirals are often contraindicated and have not been tested in immunocompromised patients. Many anti-spike monoclonal antibodies, which have been developed for over a year, are becoming ineffective against many novel SARS-CoV-2 variants of concern. Convalescent plasma is being increasingly recognized by both regulatory authorities and scientific societies as a robust therapeutic option for these patients.
In this Special Issue, we will include case series from different subsets of immunosuppressed patients (onco-haematological, rheumatological and solid organ transplant recipients) and review state-of-the-art techniques through international guidelines. Research that presents in vitro results detailing novel mechanisms of actions is also welcomed.
Dr. Daniele Focosi
Dr. Massimo Franchini
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- convalescent plasma
- COVID-19
- immunosuppression
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
